The purpose of the Biostatistics Core is to provide professional expertise in biostatistics and bioinformatics for all Breast Cancer SPORE projects, investigators, and participants. Functions provided by this core include development of experimental designs, power analysis, and sample size estimation;data quality control statistical/bioinformatic analysis and interpretation of findings;and collaboration on presentation of results. To achieve these functions, the core director and core members are constantly available to investigators, and are in regular contact with project and core leaders. The primary objectives ofthe Biostatistics Core are: 1. To provide study design and review all laboratory, animal, and clinical studies including feasibility assessment, power analysis, and sample size estimation 2. To collaborate in project data analysis, interpretation of results, and the writing of final study reports and manuscripts 3. To work with the Pathology &Tissue Informatics Core and Imaging Core in the development of research project databases, to maintain data quality control and to ensure timely data capture 4. To develop and evaluate statistical/bioinformatic methods for experimental design and data analysis Biostatistics Core support is required in all Breast Cancer SPORE studies. Core personnel have worked and will continue to work closely with project leaders to ensure the core provides state-of-the-art statistical/bioinformatic support.
The relevance of the Biostatistics Core lies in our provision of services essential for the conduct of high-quality collaborative breast cancer research;sound statistical/bioinformatics inputs are critical throughout the lifespan of a research project, from conception to completion.
|Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249|
|Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435|
|Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017|
|Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21|
|Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194|
|Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248|
|Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :|
|Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858|
|Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191|
|Jovanovi?, Bojana; Sheng, Quanhu; Seitz, Robert S et al. (2017) Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer 17:241|
Showing the most recent 10 out of 341 publications